Emicrania: nuova cura con Rimegepant | La svolta che può cambiare la vita di 5 milioni di italiani

Migraines affect 5 million Italians and cost the country €20 billion a year. In this Pianeta Salute TG report, discover how medical research is opening new perspectives with Rimegepant, the innovative drug for the treatment and prevention of migraines, which can finally restore a life free from pain. Migraines are not just a simple headache; they are a complex neurological disease that affects the personal, work, and social lives of millions of people. Today, research has made a breakthrough with Rimegepant, a drug capable of acting both in the acute phase and in preventing attacks, improving patients' quality of life and offering new hope in the management of chronic migraines. Experts explain the symptoms of migraines, the difference between the various forms (with and without aura), and the latest therapeutic strategies that aim not only to relieve pain but also to effectively prevent it. 💬 In this report, neurologists delve deeper into: • How to recognize migraine symptoms and when to contact headache centers; • New anti-CGRP therapies, effective and well-tolerated; • The role of information and awareness in the treatment process; • Pfizer's research commitment to speeding up diagnosis and improving patient care. Migraine is the second leading cause of disability in the world and is still too often underestimated: greater awareness is the first step towards early diagnosis and targeted treatments. 👉 Subscribe to Pianeta Salute TV and activate the bell 🔔 to never miss upcoming insights on health, medicine, and prevention. #migraine #Rimegepant #headache #neurology #PianetaSaluteTG Interviews with: Professor Alessandro Padovani, Director of the Neurology Clinic at the University of Brescia and President of the Italian Society of Neurology (SIN); Professor Piero Barbanti, President of the Italian Association for the Fight Against Headaches (AIC), Professor of Neurology and Sports at the San Raffaele Online University in Rome, and Director of the Headache and Pain Treatment and Research Unit at the IRCCS San Raffaele; Alessandra Sorrentino, President of the Headache Allergy Association (Al.Ce) of the Cirna Foundation Onlus; Barbara Capaccetti, Medical Director of Pfizer in Italy. ********************* 🔥 Follow us! Web TV: https://PianetaSalute.TV Magazine: https://www.PianetaSalute.online Instagram:   / pianetasalute2.0   Twitter:   / pianetasalute   Facebook:   / pianetasalute   Linkedin:   / pianeta-salute-tv   WhatsApp: https://whatsapp.com/channel/0029VaDP... Telegram: https://t.me/pianetasalute Digital terrestrial: National Channel 221 Pianeta Salute TV (00:00) - Migraine in Italy: numbers and socioeconomic impact (00:31) - Rimegepant: a new opportunity Therapeutic (00:46) - Symptoms and characteristics of migraine (03:01) - Migraine management: patient autonomy and the role of the neurologist (04:00) - Gepant drugs: innovation in migraine treatment (05:22) - Rimegepant: efficacy, tolerability, and dual action (08:02) - Quality of life for headache patients (09:54) - Pfizer's commitment to migraine research and awareness